Showing 1 - 7 results of 7 for search 'Frederick S. Vizeacoumar (14851118)', query time: 0.01s Refine Results
  1. 1
    Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S4 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy by Amr El Zawily (14851115)

    Published 2025
    Other Authors: “…Frederick S. Vizeacoumar (14851118)…”
    Save to List
    Saved in:
  2. 2
    Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S7 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy by Amr El Zawily (14851115)

    Published 2025
    Other Authors: “…Frederick S. Vizeacoumar (14851118)…”
    Save to List
    Saved in:
  3. 3
    Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S5 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy by Amr El Zawily (14851115)

    Published 2025
    Other Authors: “…Frederick S. Vizeacoumar (14851118)…”
    Save to List
    Saved in:
  4. 4
    Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy by Amr El Zawily (14851115)

    Published 2025
    Other Authors: “…Frederick S. Vizeacoumar (14851118)…”
    Save to List
    Saved in:
  5. 5
    Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S6 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy by Amr El Zawily (14851115)

    Published 2025
    Other Authors: “…Frederick S. Vizeacoumar (14851118)…”
    Save to List
    Saved in:
  6. 6
    Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S1 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy by Amr El Zawily (14851115)

    Published 2025
    Other Authors: “…Frederick S. Vizeacoumar (14851118)…”
    Save to List
    Saved in:
  7. 7
    Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy

    Supplementary Table S2 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy by Amr El Zawily (14851115)

    Published 2025
    Other Authors: “…Frederick S. Vizeacoumar (14851118)…”
    Save to List
    Saved in:

Search Tools: